Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

Oncogene

Volumn 26, Issue 25, 2007, Pages 3704-3713

  Leonard, J P ^a   Goldenberg, D M ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

B cell; CD20; CD22; Efficacy; Epratuzumab; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD22 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; EPRATUZUMAB IN 111 CONJUGATE; EPRATUZUMAB Y 90 CONJUGATE; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL;

EID: 34249664979     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210370     Document Type: Review

References (111)

1. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. (2002). Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20: 3885-3890.
2. Armitage J. (1993). Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023-1030.
3. Baum RP, Niesen A, Hertel A, Adams S, Koujouharoff G, Goldenberg DM et al. (2004). Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73(Suppl 3): 896-899.
4. 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 55: 5771s-5773s.
5. Behr TM, Holler E, Gratz S. (2002). CD22 is a suitable target molecule for detection and high-dose, myoablative radio-immunotherapy with the monoclonal antibody LL2 in acute lymphatic leukaemia and Waldenström's macroglobulinemia. Tumor Targeting 3: 32-40.
6. Behr TM, Wö rmann B, Gramatzki M, Riggert J, Gratz S, Behe M et al. (1999). Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies. Clin Cancer Res 5: 3304s-33314s.
7. 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res 55: 5764s-5770s.
8. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52: 6476-6481.
9. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ et al. (2007). Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44: 1331-1341.
10. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T et al. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9: 3982s-3990s.
11. Cesano A, Gayko U, Brannan C. (2002). Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted immunotherapy [abstract]. Blood 100: 350a.
12. Chaouchi N, Vazquez A, Calanaud P, Laprince C. (1995). B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol 154: 3096-3104.
13. 90Y doses [abstract 447]. Proc Soc Nucl Med, 52nd Annual Meeting, 155P.
14. Cheson BD. (2003). Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391-398.
15. Cheson BD. (2005). The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19: 309-322.
16. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ et al. (2002). Anti-CD20 antibody (IDECC2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplstic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87: 33-43.
17. Coffey J, Hodgson DC, Gospodarowicz MK. (2003). Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1): S28-S36.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
19. Coiffier B. (2005). State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23: 6387-6393.
20. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. (1998). Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927-1932.
21. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. (2004). Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22: 4711-4716.
22. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143.
23. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A et al. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10: 7792-7798.
24. Dörken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S et al. (1986). HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136: 4470-4479.
25. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. (2006). Intitial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8, Apr: 21;8(3):R74 [Epub ahead of print].
26. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D et al. (2006). Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106: 616-622.
27. Emmanouilides C, Leonard JP, Schuster SJ. (2004). Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (BLBCL) [abstract]. Proc Am Soc Clin Oncol 23: 6580.
28. Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH et al. (1993). The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J Immunol 150: 4719-4732.
29. Engel P, Wagner N, Miller A, Tedder TF. (1995). Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181: 1581-1586.
30. Fisher RI, Miller TP, O'Connor OA. (2004). Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program), 221-226.
31. Friedberg JW, Fisher RI. (2004). Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 4: 18-26.
32. Furman RR, Coleman M, Muss D, Leonard JP. (2006). Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer Treat Res 131: 141-159.
33. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS et al. (1986). Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4: 1470-1480.
34. Gasparini M, Bombardieri E, Tondini C, Maffioli L, Hughes L, Burraggi GL et al. (1995). Clinical utility of radio-immunoschintigraphy of non-Hodgkin's lymphoma with radiolabeled LL2 monoclonal antibody, Lymphoscan™, preliminary results. Tumori 81: 173-178.
35. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. (2004). Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103: 4416-4423.
36. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. (2000). Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908.
37. Goldenberg DM. (2001). The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39: 195-201.
38. Goldenberg DM. (2003). Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52: 281-296.
39. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H et al. (1991). Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548-564.
40. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R et al. (2004). Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5: 98-101.
41. Greiner TC, Medeiros LJ, Jaffe ES. (1995). Non-Hodgkin's lymphoma. Cancer 75: 370-380.
42. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. (2003). 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44: 77-84.
43. Grillo-Lopez AJ. (2000). Rituximab: an insider's historical perspective. Semin Oncol 27(Suppl 12): 9-16.
44. Hainsworth JD. (2004). Prolonging remission with rituximab maintenance therapy. Semin Oncol 31: 17-21.
45. Harjunpaa A, Junnikkala S, Meri S. (2000). Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634-641.
46. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R et al. (2005). Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23: 6394-6399.
47. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. (2005). Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-êB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65: 264-276.
48. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics 2006. CA Cancer J Clin 56: 106-130.
49. Johnson P, Glennie M. (2003). The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30(Suppl 2): 3-8.
50. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R et al. (1995). Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55: 5899s-55907s.
51. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5: 3292s-33303s.
52. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR et al. (1992). Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10: 1696-1711.
53. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441-449.
54. Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, De Bellard ME et al. (1994). Sialoadhesis, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 4: 965-972.
55. Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I. (1993). Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab′ induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 15: 819-825.
56. Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. (2002). Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 17: 689-697.
57. Law CL, Torres RM, Sundberg HA, Parkhouse RM, Brannan CI, Copeland NG et al. (1993). Organization of the murine Cd22 locus. Mapping to chromosome 7 and characterization of two alleles. J Immunol 151: 17-87.
58. Leonard JP. (2005). Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology (Am Soc Hematol Educ Program), 335-339.
59. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR et al. (2005a). Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23: 5044-5051.
60. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR et al. (2003). Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21: 3051-3059.
61. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW et al. (2005b). Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10: 5327-5334.
62. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB et al. (1995). Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 32: 1413-1427.
63. 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 11: 5215-5222.
64. 131Ilabeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 5: 3287s-3291s.
65. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol 41: 297-303.
66. Maloney DG, Smith B, Rose A. (2002). Rituximab: mechanism of action and resistance. Semin Oncol 29: 2-9.
67. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
68. Micallef INM, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP et al. (2006). A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107: 2826-2832.
69. Morschhauser F, Huglo D, Martinelli G. (2004). Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial [abstract 130]. Blood 104: 41a.
70. Morschhauser F, Leonard JP, Coiffier B. (2005). Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma [abstract]. Blood 106: 683a.
71. Murthy S, Sharkey RM, Goldenberg DM, Lee RE, Pinsky CM, Hansen HJ et al. (1992). Lymphoma imaging with a new technetium-99m labelled antibody, LL2. Eur J Nucl Med 19: 394-401.
72. Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE et al. (2001a). Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. Crit Rev Oncol Hematol 39: 79-86.
73. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. (2001b). Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97: 528-535.
74. Nitschke L. (2005). The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Op. Immunol 17: 290-297.
75. Nitschke L, Carsetti B, Ocker B, Kohler G, Lamers MC. (1997). CD22 is a negative regulator of B-cell receptor signaling. Curr Biol 7: 133-143.
76. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. (1996). Hyperresponsive B cells in CD22-deficient mice. Science 274: 798-801.
77. Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD et al. (1996). CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384: 634-637.
78. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM. (1989). Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49: 4568-4577.
79. 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 9: 3995s-34002s.
80. Press OW. (2003). Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 30: 10-21.
81. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R et al. (1989). Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7: 1027-1038.
82. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML et al. (1996). CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5: 551-562.
83. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44: 2000-2018.
84. Sharkey RM, Burton J, Goldenberg DM. (2005). Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol 1: 47-62.
85. Sharkey RM, Goldenberg DM. (2005). Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46(Suppl 1): 115s-1127s.
86. Shih LB, Lu HH, Xuan H, Goldenberg DM. (1994). Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56: 538-545.
87. Siegel JA, Goldenberg DM, Sharkey RM. (1991). Tumor and organ dosimetry for I-131 LL2 (EPB2) monoclonal antibody in patients with B-cell lymphomas. Antib Immunconjug Radiopharm 4: 649-654.
88. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. (2004). Radiolabeled antibody therapy in non-Hodgkin's lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 30: 165-172.
89. Skarin AT, Dorfman DM. (1997). Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin 47: 351-372.
90. Skvortsova I, Popper BA, Skvortsov S, Haidenberger A, Saurer M, Gunkel AR et al. (2005). Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo) 46: 241-248.
91. Stamenkovic I, Seed B. (1990). The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 344: 74-77.
92. Stein R, Belisle E, Hansen HJ, Goldenberg DM. (1993). Epitope specificity of the anti-B cell lymphoma monoclonal antibody, LL2. Cancer Immunol Immunother 37: 293-298.
93. Stein R, Qu Z, Chen S, Rosario A, Horak ID, Hansen HJ et al. (2004). Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10: 2868-2878.
94. Stein R, Shih LB, Sharkey RM, Hansen HJ, Goldenberg DM. (1994). Immu-RAIDt-LL2 [Tc-99 m] and Immu-RAIT™-LL2 [I-131]. Drugs Future 18: 997-1004.
95. Steinfeld SD, Youinou P. (2006). Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert opin Biol Ther 6: 943-949.
96. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al. (2006). Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8: R129.
97. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL et al. (2006). Multicenter phase-II trial of immunotherapy with humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24: 3880-3886.
98. Tedder TF, Poe JC, Haas KM. (2005). CD22: A multi-functional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88: 1-50.
99. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H et al. (2004). Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
100. Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC. (2004). Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen. Biotechnol Annu Rev 10: 265-295.
101. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. (1999). CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94: 1382-1393.
102. Vose JM. (2004). Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9: 160-172.
103. 131I-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 38: 91-101.
104. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43: 267-272.
105. Wilson CL, Fox CH, Fauci AS, Kehrl JH. (1991). CDNA cloning of the B-cell membrane protein CD22: A mediator of B-B-cell interactions. J Exp Med 173: 137-146.
106. Wilson GL, Najfeld V, Kozlow E, Menniger J, Ward D, Kehrl JH. (1993). Genomic structure and chromosomal mapping of the human CD22 gene. J Immunol 150: 5013-5024.
107. Winter JN, Gascoyne RD, Besien KV. (2004). Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program), 203-220.
108. Witzig TE. (2004). Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barcelona) 40: 111-119.
109. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463.
110. Zelenetz AD, Vose J. (2002). Patients with transformed low-grade lymphoma attain durable responses following out-patient radioimmunotherapy with toxitumomab and iodine I-131 toxitumomab (Bexxar) [abstract]. Blood 100: 357a.
111. Zinzani PL. (2005). Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 32(Part 2): 4-10.